Checkpoint Therapeutics Inc.

05/12/2021 | Press release | Distributed by Public on 05/12/2021 06:08

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma